Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer

Publication Date: April 19, 2023

Key Points

Key Points

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality among patients with cancer.

Patients with cancer are significantly more likely to develop VTE than people without cancer and experience higher rates of VTE recurrence and bleeding complications during VTE treatment.

Comprehensive management of VTE in patients with cancer includes both the identification of patients who are most likely to benefit from pharmacologic prophylaxis, as well as effective treatment to reduce the risk of VTE recurrence and mortality.

The current update adds apixaban as an option for the treatment of VTE in patients with cancer, and addresses recent evidence regarding direct factor Xa inhibitors for extended postoperative thromboprophylaxis.

Treatment

Treatm...

...lized patients who have active malignancy...


...ients who have active malignancy without...


...ologic thromboprophylaxis should n...


...rmacologic thromboprophylaxis should not be of...


...outpatients with cancer (Khorana sco...


...h multiple myeloma receiving thali...


...nts with malignant disease undergoing major s...


...phylaxis with UFH or LMWH should be commenced pre...


...methods may be added to pharmacologic t...


...regimen of pharmacologic and mechani...


...ic thromboprophylaxis for patients...


...nded pharmacologic thromboprophylaxis for...


...dated) Patients who are candidates for ex...


...dated) Alternatively, patients may be off...


...Initial anticoagulation may involve LMWH, UFH,...


...ng-term anticoagulation, LMWH, edoxaban, ri...


...gulation with LMWH, direct factor Xa inhibitors...


...ed on expert opinion in the absence of randomi...


...sertion of a vena cava filter may...


...s with primary or metastatic centr...


...and deep vein thrombosis should be tre...


...of isolated subsegmental PE or splan...


...se is not recommended to improve survival in pat...


...e is substantial variation in risk...


...d members of the oncology team should educate pati...


...es regarding off-label use in guideline recommend...


...Predictive Model for Chemotherapy-associ...